Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Recent studies suggest a primary role of oxidative stress in an early phase of the pathogenesis of schizophrenia and a strong neurobiological link has been found between dopaminergic system dysfunction, microglia overactivation, and oxidative stress. Different risk factors for schizophrenia increase oxidative stress phenomena raising the risk of developing psychosis. Oxidative stress induced by first-generation antipsychotics such as haloperidol significantly contributes to the development of extrapyramidal side effects. Haloperidol also exerts neurotoxic effects by decreasing antioxidant enzyme levels then worsening pro-oxidant events. Opposite to haloperidol, second-generation antipsychotics (or atypical antipsychotics) such as risperidone, clozapine, and olanzapine exert a strong antioxidant activity in experimental models of schizophrenia by rescuing the antioxidant system, with an increase in superoxide dismutase and glutathione (GSH) serum levels. Second-generation antipsychotics also improve the antioxidant status and reduce lipid peroxidation in schizophrenic patients. Interestingly, second-generation antipsychotics, such as risperidone, paliperidone, and in particular clozapine, reduce oxidative stress induced by microglia overactivation, decreasing the production of microglia-derived free radicals, finally protecting neurons against microglia-induced oxidative stress. Further, long-term clinical studies are needed to better understand the link between oxidative stress and the clinical response to antipsychotic drugs and the therapeutic potential of antioxidants to increase the response to antipsychotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763 · cited 2×
“It is well known that the typical antipsychotics produce EPS, including TD [55], representing the major limitation of the use of these drugs.”
BackgroundLeucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 1×
“In particular, clozapine or olanzapine treatment in schizophrenic children has been associated with abnormalities in cholesterol and triglycerides levels [24], while it has been associated to an increased risk of T2DM in addition to weight gain in adult schizophrenic patients [25,26].”
BackgroundOwen, M. J., Sawa, A., & Mortensen, P. B. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01121-6 · Cited by 1,870
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742 · cited 1×
“As demonstrated by meta-analysis studies, schizophrenia is associated with immune system dysfunction, including aberrant cytokine levels [62]; in particular, it has been shown that interleukin-1β (IL-1β), interleukin-6 (IL-6), and transforming growth factor-beta 1 (TGF-β1) can be considered state markers, since they a…”
BackgroundVancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015) · World Psychiatry · doi:10.1002/wps.20252 · Cited by 1,271 · cited 1×
“Despite the improved safety and tolerability profile compared with FGAs, the use of second-generation antipsychotic medication has been associated to unwanted side effects’ safety issues, among which metabolic alterations, such as high levels of glucose, hyperlipidemia, and obesity as well as to the development of typ…”
BackgroundHomayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 1×
“Oxidative stress may be involved in the early stage of the pathological course of schizophrenia [10], leading to parvalbumin-positive interneuron dysfunction in the young adult cortex [11]; indeed, the hypofunction of parvalbumin GABAergic interneurons causes an increased glutamate release, which in turn over-stimulat…”
BackgroundInflammation in CNS neurodegenerative diseases
Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018) · Immunology · doi:10.1111/imm.12922 · Cited by 966 · cited 1×
“As a consequence of the repair mechanism’s failure, an exacerbated or chronic inflammatory state underlies the progression of neurodegenerative events in different neuropsychiatric disorders including schizophrenia [60].”
BackgroundAtypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Vancampfort, D., Correll, C. U., Galling, B., Probst, M., De Hert, M., Ward, P. B., Rosenbaum, S., Gaughran, F., Lally, J., & Stubbs, B. (2016) · World Psychiatry · doi:10.1002/wps.20309 · Cited by 659
Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations.
Müller, N. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby024 · Cited by 648 · cited 1×
“Inflammatory reactions could be both beneficial (neuroprotective) and detrimental (neurotoxic) to the CNS, depending on the interactions occurring between environmental factors, genetic variations, and various components of the inflammatory response [59].”
BackgroundThe role of inflammation and microglial activation in the pathophysiology of psychiatric disorders
Réus, G. Z., Fries, G. R., Stertz, L., Badawy, M., Passos, I. C., Barichello, T., Kapczinski, F., & Quevedo, J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.018 · Cited by 594
Gawryluk, J. W., Wang, J.-F., Andreazza, A. C., Shao, L., & Young, L. T. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000805 · Cited by 594 · cited 2×
“, the levels of reduced (GSH), oxidized (GSSG), and total glutathione, the major free radical scavenger in the brain, were significantly decreased in post mortem PFC from schizophrenic patients [70].”
BackgroundCytokines and schizophrenia: microglia hypothesis of schizophrenia
Monji, A., Kato, T., & Kanba, S. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.01945.x · Cited by 508 · cited 2×
“That led to the development of “microglia hypothesis of schizophrenia” [163,164] (Figure 1).”
BackgroundSolleiro-Villavicencio, H., & Rivas-Arancibia, S. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00114 · Cited by 463
Merritt, K., Egerton, A., Kempton, M. J., Taylor, M. J., & McGuire, P. K. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0442 · Cited by 367 · cited 1×
“Indeed, the overactivation of glutamatergic system in the medial prefrontal cortex (mPFC) is considered a pathophysiological hallmark of schizophrenia and an increased glutamate efflux in prefrontal cortex (PFC) plays a significant role in the development/progression of both positive and negative symptoms [30,36,37].”
BackgroundAltered glutathione redox state in schizophrenia.
Yao, J. K., Leonard, S., & Reddy, R. (2006) · Disease Markers · doi:10.1155/2006/248387 · Cited by 321
Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Mailman, R., & Murthy, V. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361461 · Cited by 311
Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization
Howes, O. D., & McCutcheon, R. (2017) · Translational Psychiatry · doi:10.1038/tp.2016.278 · Cited by 288
Antioxidants, Redox Signaling, and Pathophysiology in Schizophrenia: An Integrative View
Yao, J. K., & Keshavan, M. S. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3603 · Cited by 285 · cited 1×
“Oxidative and nitrosative stress processes generate alterations in the physiological redox state of cells, leading to excessive peroxides and free radical production with highly toxic effects [66].”
BackgroundKristiansen, L. V., Beneyto, M., Haroutunian, V, & Meador-Woodruff, J. H. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001844 · Cited by 220
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery
Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Slifstein, M., Javitt, D. C., Lieberman, J. A., Abi-Dargham, A., & Girgis, R. R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.136 · Cited by 205
Juvenile Antioxidant Treatment Prevents Adult Deficits in a Developmental Model of Schizophrenia
Cabungcal, J.-H., Counotte, D. S., Lewis, E. M., Tejeda, H. A., Piantadosi, P., Pollock, C., Calhoon, G. G., Sullivan, E. M., Presgraves, E., Kil, J., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.07.028 · Cited by 204 · cited 2×
“that oxidative stress plays a central role in the development of late onset psychosis [71].”
BackgroundDakhale, G. N., Khanzode, S. D., Khanzode, S. S., & Saoji, A. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0117-1 · Cited by 131
Schiavone, S., Colaianna, M., & Curtis, L. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150105143358 · Cited by 129
Inhibitory Interneurons, Oxidative Stress, and Schizophrenia
Sullivan, E. M., & O'Donnell, P. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs052 · Cited by 71 · cited 1×
“Oxidative stress may be involved in the early stage of the pathological course of schizophrenia [10], leading to parvalbumin-positive interneuron dysfunction in the young adult cortex [11]; indeed, the hypofunction of parvalbumin GABAergic interneurons causes an increased glutamate release, which in turn over-stimulat…”
BackgroundThe Many Faces of Mitochondrial Dysfunction in Depression: From Pathology to Treatment
Caruso, G., Benatti, C., Blom, J. M. C., Caraci, F., & Tascedda, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00995 · Cited by 65 · cited 1×
“Oxidative stress refers to a phenomenon characterized by the homeostatic imbalance between the production of pro-oxidant species, such as reactive oxygen (ROS) and nitrogen (RNS) species, and the ability of antioxidant systems to neutralize them [8,9].”
BackgroundSelf-citation
Cited by
Chakhtouna, H., Benzeid, H., Zari, N., Qaiss, A. E. K., & Bouhfid, R. (2021) · Separation and Purification Technology · doi:10.1016/j.seppur.2021.118592 · Cited by 145
De Simone, G., Mazza, B., Vellucci, L., Barone, A., Ciccarelli, M., & de Bartolomeis, A. (2023) · Antioxidants · doi:10.3390/antiox12040975 · Cited by 49
Goh, X. X., Tang, P. Y., & Tee, S. F. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114429 · Cited by 25
Blood-Based Oxidation Markers in Medicated and Unmedicated Schizophrenia Patients: A Meta-Analysis
Goh, X. X., Tang, P. Y., & Tee, S. F. (2022) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102932 · Cited by 24
Metadata
- Authors
- Caruso, G., Grasso, M., Fidilio, A., Tascedda, F., Drago, F., & Caraci, F.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2020-12-12
- Volume
- 13
- Issue
- 12
- Pages
- 457
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W3112832611
- Cited by
- 87
- References
- 27
- FWCI
- 8.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.